Due to the challenges associated with treating ovarian cancer, much effort has been devoted to identifying new therapeutic approaches for the disease [51], including recent promising results for PARP inhibition for patients with BRCA1/2 mutations [10]. The gene discussed is BRCA1; the disease is ovarian carcinoma.